Search research articles
Contact Us
Filters
Showing results (521-530 of 567) with videos related to
Page
of 57
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
Toni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
ESMO Open
|
January 15, 2025
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes
W Xu, G Birch, A Meliki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L Topalian, Mario Sznol, David F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
N M Tannir, L Albigès, D F McDermott, et al.
Nature Medicine
|
May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Kobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
July 17, 2004
Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem
P F McDermott, S M Bodeis, F M Aarestrup, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Cancer Immunology Research
|
June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Renee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 57
Search research articles
Search
Showing results (521-530 of 567) with videos related to
Sort By:
Page
of 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
Toni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
ESMO Open
|
January 15, 2025
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes
W Xu, G Birch, A Meliki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L Topalian, Mario Sznol, David F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
N M Tannir, L Albigès, D F McDermott, et al.
Nature Medicine
|
May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Kobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
July 17, 2004
Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem
P F McDermott, S M Bodeis, F M Aarestrup, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Cancer Immunology Research
|
June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Renee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 57